title: Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.
abstract: OBJECTIVE
  Recent data show that Imatinib mesylate (IM) also affects haematopoietic stem cells (HSC), T lymphocytes and dendritic cells that do not harbour constitutively active tyrosine kinases.
  
  
  METHODS
  We evaluated possible effects of IM on human bone marrow-derived mesenchymal stem cells (MSC) in vitro.
  
  
  RESULTS
  Screening the activity of 42 receptor tyrosine kinases revealed an exclusive inhibition of platelet-derived growth factor receptorbeta (PDGFRbeta). Analysis of downstream targets of PDGFRbeta demonstrated IM-mediated reduction of Akt and Erk1/2 phosphorylation. Culture of MSC with IM led to the reversible development of perinuclear multi-vesicular bodies. The proliferation and clonogenicity of MSC were significantly reduced compared to control cultures. IM favoured adipogenic differentiation of MSC whereas osteogenesis was suppressed. The functional deficits described led to a 50% reduction in the support of clonogenic haematopoietic stem cells, cultured for 1 month on a monolayer of MSC with IM.
  
  
  CONCLUSIONS
  In summary, inhibition of PDGFRbeta and downstream Akt and Erk signalling by IM has a significant impact on proliferation and differentiation of human MSC in vitro.
authors.affiliation: Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus, Dresden, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Fierro
authors.forename: T
authors.initials: T
authors.lastname: Illmer
authors.forename: D
authors.initials: D
authors.lastname: Jing
authors.forename: E
authors.initials: E
authors.lastname: Schleyer
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: S
authors.initials: S
authors.lastname: Boxberger
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
mesh_terms: D017667:Adipocytes / Q000166:cytology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002999:Clone Cells; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D020935:MAP Kinase Signaling System / Q000187:drug effects; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000187:drug effects*; D010011:Osteocytes / Q000166:cytology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019869:Phosphatidylinositol 3-Kinases; D020797:Receptor, Platelet-Derived Growth Factor beta; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases